Market Overview

BioSymetrics Announces Strategic Advisory Board

Share:

Advisors include accomplished research executives and thought
leaders in fields of cardiovascular and precision medicine, genomics,
and biopharmaceuticals

BioSymetrics Inc., a biomedical AI company, today announced the
formation of its Strategic Advisory Board (SAB). The newly-formed SAB
will work closely with BioSymetrics' leadership team to further the
company's mission of advancing healthcare and R&D innovation via machine
learning and integrated analytics. The SAB is comprised of world-class
clinicians, academic researchers, data scientists and healthcare
technologists who are recognized for their leadership in cardiovascular
medicine, neurosurgery, genomics, healthcare, biopharmaceuticals, and
precision medicine.

Led by Chairman of the Board Anthony Iacovone, and Chief Scientific
Officer Gabriel Musso, the following accomplished and well-credentialed
members will provide scientific expertise and business counsel to
BioSymetrics: Paul Boutros, MBA, PhD; Robert
DeVita, MS, PhD; Chinnappa Kodira, MS; Calum MacRae, MD, PhD; and Gene
Salkind, MD.

"We are honored to collaborate with visionary scientists whose R&D
achievements and product innovations have contributed to advances in
healthcare and medicine," said Dr. Musso. "Our esteemed advisory board
members will be leveraged as a strategic resource in market initiatives,
and will add significant input and impact to the design of more
BioSymetrics Data Science tools and Machine Learning solutions."

Strategic Advisory Board Members:

Calum MacRae, MD, PhD is the Vice Chair for
Scientific Innovation at Brigham and Women's Hospital (BWH), an
Associate Professor of Medicine at Harvard Medical School, and co-chair
of BWH's Genomic Medicine Program. Dr. MacRae's lab at BWH is focused on
understanding the mechanisms of cardiovascular disease and their therapy
using human studies and complementary high-throughput biology in the
zebrafish. As a member of the Harvard Stem Cell Institute, Dr. MacRae's
interests include the role of functional inputs, such as mechanical or
electrical forces, in refining cardiovascular development. He is also
the leader of the "One Brave Idea" project to fight coronary heart
disease, a $75 million initiative funded by the American Heart
Association, Verily, and Astra Zeneca.

Chinnappa Kodira, MS is the Managing
Partner for an advanced analytics consultancy that serves life sciences
and healthcare organizations. Most recently he served as Head of
Computational Modeling, and Bioinformatics Strategy Leader at GE Global
Research where he led the efforts on developing integrated data analytic
solutions using omics, pathology, imaging and clinical data for accurate
patient stratification, disease scoring and network modeling for
research applications in oncology, immunology and neurodegenerative
diseases. Prior to GE, his work included building first-in-class R&D
applications for the reference human genome mapping, target
identification and biomarker discovery at Celera Genomics, Roche
Diagnostics and the Broad Institute of MIT and Harvard. At the Broad, he
served as the Director of genome annotation where he led development and
application of genome analysis pipelines for multiple high-profile
genome projects. He was a key member of the early jumpstart phase of the
Human Microbiome Reference Consortium. Earlier in his career, he did
experimental and computational research at the National Center for
Genome Resources (Santa Fe, New Mexico) and Sealy Center for Molecular
Science.

Paul Boutros, MBA, PhD is a Principal
Investigator at the Ontario Institute for Cancer Research (OICR), and
Associate Professor in the Departments of Pharmacology and Toxicology,
and Medical Biophysics at the University of Toronto. Dr. Boutros also
serves as the co-lead of the Canadian Prostate Cancer Genome Network
(CPC-GENE) and has led somatic mutation calling challenges for the
worldwide bioinformatics community. Dr. Boutros' laboratory uses
genome-scale datasets to identify patient specific cancer biomarkers,
allowing application of personalized therapeutics for all cancer types,
although specifically focused on prostate cancer. His research focuses
on novel methods for integrating predictive analytics, outcomes, and
molecular biology into new diagnostic applications and oncology R&D
advances.

Robert DeVita, MS, PhD is a Professor at
the Icahn School of Medicine at Mount Sinai, in the Department of
Pharmacological Sciences. He also serves as Director of the Medicinal
Chemistry Core of the Drug Discovery Institute (DDI) at Mt Sinai, and is
on the SAB of Circumvent, as well as being a co-founder of Attenua, Inc,
and advisor for Mitokinin, Inc. Dr. DeVita has over 25 years of
experience in the biopharmaceutical industry, including at Merck
Research Laboratories as director of medicinal chemistry. His work spans
the drug discovery paradigm from target identification through clinical
stage development, and the identification of multiple development
candidates including two Phase II clinical compounds for CNS and CV
targets. Dr. DeVita also has experience in the discovery and development
of PET imaging agents and translational biomarkers for CNS targets. He
has developed, in collaboration with cross-disciplinary teams, orally
active, brain penetrant, peripheral and GI tract drug targeting
strategies. His R&D background across a range of therapeutic areas
includes Oncology, CNS, pain, inflammation, diabetes, cardiovascular,
hypertension, obesity, urology, and endocrinology.

Gene Salkind, MD currently serves as
Chairman of Neurosurgery at Holy Redeemer Hospital in Pennsylvania. Dr.
Salkind has practiced neurosurgery in the Philadelphia area for over 30
years, and previously served as Chairman of Neurosurgery at the Albert
Einstein Medical Center. He has been a Director of DermTech
International since May 2007 and serves on several other boards,
including the SAB for Cure Pharmaceuticals. Dr. Salkind has published
multiple papers and held professorships at leading teaching hospitals
including the University of Pennsylvania Medical School.

"BioSymetrics is enabling healthcare organizations to intelligently
manage large-scale complex data. I believe our machine learning methods
and automated pre-processing framework will be a foundational part of
biomedical digital transformation and future AI applications. I look
forward to the contributions from this esteemed group of industry
leaders to help us continue to excel," said BioSymetrics' Board Chairman
Anthony Iacovone.

The BioSymetrics technology offering is a SaaS-based biomedical Machine
Learning (ML) platform, Augusta™, that enables customers to perform
automated ML and data pre-processing. Augusta's automated iteration
framework addresses the step in ML that is the most time consuming and
error-prone, that of cleaning and pre-processing unstructured data for
analysis. Augusta performs member-level predictive analytics on many
kinds of R&D, precision medicine, and healthcare data. The Augusta
platform can work from raw data formats, applies robust feature
selection methods, and conducts integrated analytics on siloed data and
complex data types e.g. compound chemistry, genomics, metabolomics,
precision medicine, lab testing data, ECG/EKG, medical imaging data, and
more. As outlined in a recent white
paper
, Augusta provides over 150 data modules.

About
BioSymetrics

BioSymetrics Inc. is based in New York,
Boston, and Toronto. Serving hospitals and health systems and
biopharmaceutical, precision medicine, and technology companies,
BioSymetrics is empowering healthcare and R&D innovation with leading
data science and analytics expertise, focused on making end-to-end
machine learning accessible to scientists and life sciences
organizations. For more information, visit www.biosymetrics.com
and Twitter @biosymetrics.

View Comments and Join the Discussion!